[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"venom-allergy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:venom-allergy":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,44,72,104],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100583452","identification-of-b-regulatory-cells-by-flow-cytometry-100583452",false,"NCT06876506","Identification of B Regulatory Cells by Flow Cytometry","Identification and Quantitation of Human B Regulatory Cells Via Flow Cytometry and Their Potential Role as a Treatment Efficacy Biomarker in Allergen-specific Immunotherapy","Control cohort - Participants with:\n\n* No clinical and laboratory findings of IgE-mediated hypersensitivity (i.e. no clinical history of specific allergies to pollens, house dust mite or insect venoms\n* Negative serological testing for specific IgE to pollens, house dust mite and insect venoms\n* Patients aged 18 years or older\n\nTest cohort:\n\n* Participants over the age of 18 years\n* Participants with physician-diagnosed IgE-mediated allergic disease to pollens, house dust mite or insect venoms\n\nExclusion Criteria:\n\n* Patients under the age of 18 years\n* Samples from patients with IgE-mediated allergic disease, treated or untreated, specific to allergens other than pollens, house dust mite and insect venom\n* Participants who are pregnant\n* Participants who cannot adequately understand verbal and \u002F or written explanations given in English",true,"ALL","18 Years",{"count":20,"type":21},80,"ESTIMATED","OBSERVATIONAL","The goal of this laboratory and observational study is to develop a test to quantify B-regulatory cells in blood. This will be used to detect changes in B-regulatory cell populations in pollen and insect venom allergic patients who are receiving routine allergen immunotherapy treatment. The primary question this study aims to answer is;\n\n1). Are changes in blood B-regulatory cells associated with successful allergen immunotherapy treatment, and therefore do these changes suggest patients have developed a suitable level of allergen tolerance and reduction in their allergic symptoms upon re-exposure to the causal allergen.\n\nPatients will also be asked to complete quality of life questionnaire periodically throughout the study to determine if there are associations between variation in B-regulatory cell populations in blood and allergic symptoms experienced.",[25,26],"Pollen Allergy","Venom Allergy",[25,26,28,29,30],"Allergen Immunotherapy","B-regulatory cells","dust mite allergy","NOT_YET_RECRUITING","2026-06-22",{"date":34,"type":35},"2026-06-23","ACTUAL",{"date":37,"type":21},"2026-08-01",{"date":39,"type":21},"2027-09-30",{"name":41,"class":42},"Hull University Teaching Hospitals NHS Trust","OTHER_GOV",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":17,"minAge":51,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":43},"100637208","bhlmann-bat-basophil-activation-test-in-allergy-diagnosis-exploratory-pilot-study-100637208","NCT07596303","BÜHLMANN BAT (Basophil Activation Test) in Allergy Diagnosis (Exploratory Pilot Study)","Exploratory Pilot Study of BÜHLMANN Automated Basophil Activation Test as an Aid to Diagnosis of Immediate Type Allergic Disorders","Inclusion Criteria:\n\n* Individuals with diagnosis of a hypersensitivity \u002F allergy to one of the 6 allergens, established according to common clinical practice\n\nExclusion Criteria:\n\n* Pregnant women\n* Children under the age of 18 months\n* Individuals under therapy with Omalizumab or Rituximab\n* Individuals with an allergic reaction less than two weeks before blood sample collection\n* Individuals under therapy with BTK inhibitors\n* Individuals receiving allergen specific immunotherapy (ASIT)\n* Subjects with active infection and inflammatory conditions\n* Patients who are unable to understand the study information and informed consent form in German","18 Months",{"count":53,"type":21},60,"The goal of this exploratory pilot study is to generate early data needed for future validation studies of the automated BÜHLMANN BAT (Basophil activation test) assay. The main questions it aims to answer are:\n\nDoes the BAT assay use the optimal allergen concentrations for stimulation, and how do its preliminary cut-offs perform in a real-world clinical scenario?\n\nParticipants older than 1.5 years who are being evaluated for possible allergy sensitization will provide one additional blood tube during their routine blood draw as part of the regular medical care. The study involves only one visit and does not provide direct personal benefit.",[56,57,26,58,59,60],"Allergy Testing","Peanut Allergies","House Dust Mite Allergy","Hazelnut Allergy","Cat Epithelium Allergy","RECRUITING","2026-05-28",{"date":64,"type":35},"2026-06-01",{"date":66,"type":21},"2026-05",{"date":68,"type":21},"2026-08-31",{"name":70,"class":71},"Bühlmann Laboratories AG","INDUSTRY",{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":79,"targetDuration":4,"studyType":81,"phases":82,"briefSummary":84,"conditions":85,"keywords":88,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":103},"100588015","phase-4-jack-jumper-ant-venom-immunotherapy-long-term-effectiveness-investigation-100588015","NCT06935890","Jack Jumper Ant Venom Immunotherapy Long-term Effectiveness Investigation","JAVELIN","Eligibility criteria\n\n\\- Any adult (≥ 18 years) who has completed a JJA VIT program at one of the three participating sites.\n\nInclusion Criteria:\n\n1. Completed a continuous program of JJA VIT of between 3 and \\\u003C 6 years duration.\n2. Have ceased JJA VIT for ≥ 18 months but \\\u003C 5 years.\n3. Have the ability to provide informed consent.\n\nExclusion Criteria:\n\n1. Any person \\\u003C 18 years.\n2. Any adult (≥ 18 years) who has not completed a continuous JJA VIT program of duration between 3 and \\\u003C 6 years.\n3. Any adult (≥ 18 years) who has completed a continuous JJA VIT program of duration between 3 and \\\u003C 6 years but ceased JJA VIT \\\u003C 18 months or \\> 5 years ago.\n4. Any person who has a medical condition, that in the opinion of the investigator, may place them at increased risk if they were to have a sting challenge.\n5. Unable to understand study requirements and provide informed consent.",{"count":80,"type":21},100,"INTERVENTIONAL",[83],"PHASE4","Jack Jumper ant (JJA) venom allergy is a uniquely Australian medical condition. It is the leading cause of venom allergy and affects up to three per cent of the population. 70 percent of people with JJA allergy will have another reaction on a repeat sting and this sensitivity appears to persist for many years.\n\nVenom immunotherapy (VIT) has been shown to be a safe and effective treatment in the prevention of severe systemic allergic reactions (anaphylaxis) to future stings. It is currently offered to patients as standard care in Tasmania, South Australia and Victoria. However, whilst JJA VIT has been used for many years, there is a lack of evidence on the long-term benefit of the treatment and how it impacts patient quality of life.\n\nThis trial will offer patients who have completed a JJA VIT program (between 3 and \\\u003C 6-years duration) and have been off-treatment for at least 18-months and \\\u003C 5 years, to have a supervised JJA sting challenge and blood test to assess their JJA venom tolerance level. It will also ask them to complete a set of questionnaires at different timepoints to obtain a history of their exposure and reactions to JJA stings outside of the hospital setting (field stings), and to measure the impact of the completed VIT and knowledge of their sting challenge outcome on their quality of life and their behaviours around auto-injectors.\n\nThese measures will be used to explore the long-term effectiveness of JJA VIT and the impact of a sting challenge post VIT on a patient's quality of life.",[86,87,26],"Allergy","Immunotherapy",[89,90,91,92],"Jack Jumper Ant","Venom Immunotherapy","Sting challenge","VIT","2026-03-29",{"date":95,"type":35},"2026-03-31",{"date":97,"type":35},"2025-11-25",{"date":99,"type":21},"2029-10",{"name":101,"class":102},"Murdoch Childrens Research Institute","OTHER",3,{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":108,"acronym":109,"eligibilityCriteria":110,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":111,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":113,"conditions":114,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":43},"100618173","analysis-of-the-role-of-ige-proteoforms-in-health-and-disease-100618173","NCT07328178","Analysis of the Role of IgE Proteoforms in Health and Disease","IgE-PhD","Inclusion Criteria:\n\n* CSU and type I allergic diseases (including anaphylaxis and desensitization), atopic dermatitis, mastocytosis, XLA and HaT (informed consent, age: any available adult subject, gender: any available subject, clinical phenotype and specific information about the allergy (e.g. severity, medication, medical history, laboratory testing)\n* Healthy controls (informed consent, age matched to the allergic patients, gender matched to the allergic patients, patient-reported symptoms related to allergy to aeroallergens, food, drugs, hymenoptera venom, CSU)\n\nExclusion Criteria:\n\n* Absence of informed consent\n* Age \\\u003C 18 years old",{"count":112,"type":21},200,"The goal of this observational study is to evaluate the role of IgE proteoforms in healthy volunteers and in patients with type I allergy, patients with chronic spontaneous urticaria, patients with a recent history of anaphylaxis, patients with mastocytosis, patients with hereditary alpha tryptasemia, patients with X-linked agammaglobulinemia (XLA), and patients undergoing desensitization for venom or medication allergy.",[115,116,117,26,118,119,120,121,122],"Anaphylaxis","Mastocytosis","X-linked Agammaglobulinaemia","Chronic Spontaneous Urticaria (CSU)","Type I Allergy","Medication Allergy","Healthy Control","Hereditary Alpha-Tryptasemia","2025-12-26",{"date":125,"type":35},"2026-01-09",{"date":127,"type":35},"2025-01-01",{"date":129,"type":21},"2029-01-01",{"name":131,"class":102},"KU Leuven"]